Artiva Biotherapeutics, Inc. (ARTV): Free Cash Flow
-$79.34M
Year ended 2025-12-31
-$76.91M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$79.34M | n/m | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | -$55.67M | n/m | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | -$50.69M | n/a | 2025-03-24, From 2023-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | -$79.34M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $7.57M | n/m |
| Amgen Inc (AMGN) | 2025-12-31 | $8.10B | -22.1% |
| Repligen Corp (RGEN) | 2025-12-31 | $93.90M | -37.3% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$5.04M | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $263.22M | +2.6% |
| Biogen Inc. (BIIB) | 2025-12-31 | $2.05B | -24.7% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$19.44M | n/m |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $9.46B | -8.2% |
Compare ARTV, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗